Search company, investor...

Predict your next investment

Corporation
pierre-fabre.com

Investments

3

Portfolio Exits

2

Funds

1

Partners & Customers

10

About Pierre Fabre

Pierre Fabre is a French pharmaceutical group. Founded and its headquarters still based in the South-west of France, Pierre Fabre has branches in countries and distribution agreements in over 130 countries. Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide.

Headquarters Location

Avenue Hoche

Paris, 75008,

France

+33 (0)5 63.62.38.50

Want to inform investors similar to Pierre Fabre about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Pierre Fabre News

A plethora of plant molecules provides a ple"flora" of data

Jan 18, 2023

flora" of data A digitized library of 1,600 chemically-diverse plant extracts that can be of potential use in biological studies and future drug discovery GigaScience Researchers at the University of Geneva have established a searchable library of spectra and molecules found in a collection of 1,600 plant extracts. This collection was accessed through a collaboration with Pierre Fabre Laboratories. The resulting open resource, published in the journal GigaScience , shares both the obtained data and the employed methods. This will be useful for research ranging from drug discovery to the large-scale exploration of plants' chemical diversity. Plant metabolites play a fundamental role in drug development, as they can display potent biological activities; many existing drugs are used either as pure natural products (for example the anti-malarial artemisinin and anti-cancer drug taxol), or derived from natural products (such as the anti-cancer drugs vinorelbine, brentuximab vedotin). Pierre Fabre Laboratories have always been keen to share its pharmaceutical experience with academia. For instance, the anti-cancerous semi-synthetic natural product vinorelbine, which is derived from the Madagascar Periwinkle (Catharanthus roseus), was marketed in 1989 as a result of a collaboration with Professor Pierre Potier from the French National Center for Scientific Research (CNRS). Pierre Fabre Laboratories have made plant research a central aspect of its approach since its creation. A collection of plant samples was constituted over the 1998-2015 period with the main goal of finding novel anti-cancer drugs. This collection of botanical samples is one of the largest private plant libraries in the world numbering over 17,000 unique samples, including some rare species and covers a diverse range of botanical families from all over the world. Since 2015, Pierre Fabre Laboratories have opened access to their private plant samples collection for interested partners. This new study published in GigaScience reports the chemical characterization of circa 10% of the plant extracts in the Pierre Fabre Laboratories collection. This represents an important step towards making the chemical diversity of the full collection accessible to researchers around the world. The researchers at the University of Geneva used high-resolution mass spectrometry in combination with advanced computational pipelines to acquire over two million spectra and associated chemical information, providing valuable insights into the biochemical content of the plant extracts. The mass spectrometry profiles and associated metadata have been shared openly through the MassIVE repository (accession number MSV000087728), and this Data Note provides demonstrations on how to query this extensive curated resource. The Data Note shares both the resulting data and the employed methods, allowing for reproducibility, further exploration of the dataset and improvement of the proposed computational tools and methods. This is an exceptional resource for advancing the field of large-scale chemodiversity digitization. Such fruitful partnership between academia and industry illustrates that the fate of a historical and private collection of plant samples can be changed and that the richness of the associated chemical diversity can be made available to a wider public. Further Reading: Allard P-M et al. (2023): Open and re-usable annotated mass spectrometry dataset of a chemodiverse collection of 1,600 plant extracts. GigaScience doi: 10.1093/gigascience/giac124   Allard P-M & Wolfender, J.-L. (2021). MassIVE MSV000087728 - GNPS_PF_plant_extracts_library_dataset_01 [Data set]. MassIVE. https://doi.org/10.25345/C59J97 Allard P-M; Gaudry A; Quirós-Guerrero L; Rutz A; Dounoue-Kubo M; N Walker TW; Defossez E; Long C; Grondin A; David B; Wolfender J (2022): Supporting data for "Open and re-usable annotated mass spectrometry dataset of a chemodiverse collection of 1,600 plant extracts." GigaScience Database. http://dx.doi.org/10.5524/102323   Funding: Swiss National Science Foundation (SNFN◦CRSII5_189 921/1) Sharing on social media? Sharing on social media? About GigaScience Press GigaScience Press  is BGI's Open Access Publishing division, which publishes scientific journals and data. Its publishing projects are carried out with international publishing partners and infrastructure providers, including Oxford University Press and River Valley Technologies. It currently publishes two award-winning data-centric journals: its premier journal  GigaScience  (launched in 2012), which won the 2018 American Publishers PROSE award for innovation in journal publishing, and its new journal  GigaByte  (launched 2020), which won the 2022 ALPSP Award for Innovation in Publishing. The press also publishes data, software, and other research objects via its  GigaDB.org  database. To encourage transparent reporting of scientific research and to enable future access and analyses, it is a requirement of manuscript submission to all GigaScience Press journals that all supporting data and source code be made openly available in GigaDB or in a community approved, publicly available repository. About GigaScience GigaScience  is co-published by  GigaScience Press  and  Oxford University Press . Winner of the 2018 PROSE award for Innovation in Journal Publishing (Multidisciplinary), the journal covers research that uses or produces 'big data' from the full spectrum of the biological and biomedical sciences. It also serves as a forum for discussing the difficulties of and unique needs for handling large-scale data from all areas of the life and medical sciences. The journal has a completely novel publication format -- one that integrates manuscript publication with complete data hosting, and analyses tool incorporation. To encourage transparent reporting of scientific research as well as enable future access and analyses, it is a requirement of manuscript submission to GigaScience that all supporting data and source code be made available in the GigaScience database,  GigaDB , as well as in publicly available repositories. GigaScience will provide users access to associated online tools and workflows, and has integrated a data analysis platform, maximizing the potential utility and re-use of data. Journal

Pierre Fabre Investments

3 Investments

Pierre Fabre has made 3 investments. Their latest investment was in Ribonexus as part of their Seed VC on September 9, 2021.

CBI Logo

Pierre Fabre Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/27/2021

Seed VC

Ribonexus

$4.7M

Yes

3

4/8/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/10/2018

Corporate Minority

Subscribe to see more

Subscribe to see more

10

Date

9/27/2021

4/8/2021

1/10/2018

Round

Seed VC

Series A

Corporate Minority

Company

Ribonexus

Subscribe to see more

Subscribe to see more

Amount

$4.7M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

Pierre Fabre Portfolio Exits

2 Portfolio Exits

Pierre Fabre has 2 portfolio exits. Their latest portfolio exit was Valenza Biotech on January 05, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/5/2023

Acquired

$99M

8

11/6/2020

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/5/2023

11/6/2020

Exit

Acquired

Divestiture

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

8

10

Pierre Fabre Acquisitions

2 Acquisitions

Pierre Fabre acquired 2 companies. Their latest acquisition was Igenica Biotherapeutics on May 24, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/24/2017

Series E+

$99M

$85.73M

Asset Sale

1

1/15/2007

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2017

1/15/2007

Investment Stage

Series E+

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$85.73M

Note

Asset Sale

Subscribe to see more

Sources

1

10

Pierre Fabre Fund History

1 Fund History

Pierre Fabre has 1 fund, including Pierre Fabre Fund for Innovation.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/3/2016

Pierre Fabre Fund for Innovation

1

Closing Date

2/3/2016

Fund

Pierre Fabre Fund for Innovation

Fund Type

Status

Amount

Sources

1

Pierre Fabre Partners & Customers

10 Partners and customers

Pierre Fabre has 10 strategic partners and customers. Pierre Fabre recently partnered with Erasca on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/30/2022

Partner

United States

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

`` We are excited to work with Pierre Fabre , a leader in precision oncology , on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC , '' said Jonathan E. Lim , M.D. , Erasca 's chairman , CEO , and co-founder .

2

10/25/2022

Vendor

Italy

1

7/5/2022

Licensee

Switzerland

Pierre Fabre buys rights to Urovant’s vibegron

Urovant Sciences has entered into an exclusive license agreement with French drugmaker Pierre Fabre to register and commercialize vibegron , trade named Gemtesa , for the treatment of overactive bladder in the European Economic Area , UK , and Switzerland , with the first right of refusal for French-speaking countries of Sub-Saharan Africa , Turkey , and certain Eastern European countries .

1

6/15/2022

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

2/24/2022

Partner

China

Subscribe to see more

Subscribe to see more

10

Date

11/30/2022

10/25/2022

7/5/2022

6/15/2022

2/24/2022

Type

Partner

Vendor

Licensee

Partner

Partner

Business Partner

Country

United States

Italy

Switzerland

Switzerland

China

News Snippet

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

`` We are excited to work with Pierre Fabre , a leader in precision oncology , on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC , '' said Jonathan E. Lim , M.D. , Erasca 's chairman , CEO , and co-founder .

Pierre Fabre buys rights to Urovant’s vibegron

Urovant Sciences has entered into an exclusive license agreement with French drugmaker Pierre Fabre to register and commercialize vibegron , trade named Gemtesa , for the treatment of overactive bladder in the European Economic Area , UK , and Switzerland , with the first right of refusal for French-speaking countries of Sub-Saharan Africa , Turkey , and certain Eastern European countries .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Pierre Fabre Team

12 Team Members

Pierre Fabre has 12 team members, including former Chief Executive Officer, Olivier Bohuon.

Name

Work History

Title

Status

Olivier Bohuon

Chief Executive Officer

Former

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Olivier Bohuon

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Former

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.